Use of a biological extracellular matrix wound therapy to heal complex, chronic wounds.
This small case series involved four patients with vascular impairment and multiple comorbidities whose wounds had not responded to standard treatment. Use of this novel therapy help initiate wound healing and improve quality of life.
Rando
T
T
The Royal Melbourne Hospital, Victoria, Australia. tabatha.rando@mh.org.au
D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005109:Extracellular Matrix / Q000187:drug effects; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D007871:Leg Ulcer / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000175:diagnosis / Q000209:etiology; D011140:Polyurethanes / Q000627:therapeutic use; D012828:Silicones / Q000627:therapeutic use; D017592:Skin Care / Q000379:methods; D017768:Skin, Artificial; D053773:Transforming Growth Factor beta1 / Q000627:therapeutic use*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects*
D011140:Polyurethanes; D012828:Silicones; D053773:Transforming Growth Factor beta1; D042461:Vascular Endothelial Growth Factor A; C081143:allevyn; C114834:mepitel; D016222:Fibroblast Growth Factor 2